Author:
Casanova Clémence,Ramier Clémence,Fortin Davide,Carrieri Patrizia,Mancini Julien,Barré Tangui
Abstract
Abstract
Background
Cannabidiol (CBD), a safe, non-intoxicating cannabis component, is growing in popularity in Europe and worldwide. However, CBD EU regulation is blurry, and consequent labelling and product quality issues may have implications for public health. There is therefore a need to assess the prevalence and perceived harmfulness of CBD use in EU countries, as well as to characterise CBD users. We aimed to do so in the French population.
Methods
In December 2021, an online survey was conducted in a sample respecting the French adult population structure for key demographic variables. Sociodemographic, behavioural and CBD perception data were collected. Three separate regressions were performed to identify correlates of i) having heard of CBD, ii) using CBD, iii) perceived harmfulness of CBD. A hierarchical classification was also performed to identify profiles of CBD users.
Results
The study sample comprised 1969 adults, of whom 69.2% had heard of CBD and 10.1% used it. Less than half (46.8%) of the former considered it harmful. Having heard of CBD was associated with younger age, being born in France, tobacco use, and cannabis use. CBD use was associated with younger age, tobacco use, cannabis use, poor self-reported general health status, and positive perception of alternative medicines. Cluster analysis revealed four different CBD user profiles based on socio-demographics and behavioural characteristics.
Conclusion
Ten percent of the adults in this French study used CBD, and several user profiles emerged. Our results indirectly advocate clearer European CBD regulations to ensure safe and high-quality products.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference43 articles.
1. Russo EB. Cannabidiol Claims and Misconceptions. Trends Pharmacol Sci. 2017;38(3):198–201.
2. Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology. 2021;238(1):9–28.
3. Expert Committee on Drug Dependence. CANNABIDIOL (CBD), Critical Review Report. Geneva: World Health Organization; 2018. Available from: https://www.who.int/medicines/access/controlled-substances/CannabidiolCriticalReview.pdf. Cited 17 Jan 2022.
4. Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2020;45(11):1799–806.
5. European Monitoring Centre for Drugs and Drug Addiction. Low-THC cannabis products in Europe. Luxembourg: Publications Office of the European Union, L; 2020. Available from: https://www.emcdda.europa.eu/system/files/publications/13471/TD0320749ENN01.pdf.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献